

Amendments to the Claims:

Please amend claims 35, 36, 41, 42, 50, 56, and 57. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-16. (Canceled)

17. (Previously Presented) An antibody that specifically binds CD22, said anti-CD22 antibody having a variable light (VL) chain comprising three complementarity determining regions (CDRs), and a variable heavy (VH) chain comprising three CDRs, wherein

(i) said VL chain CDR1 has the sequence of SEQ ID NO:7, wherein positions 4-5 of SEQ ID NO:7 have an amino acid sequence selected from the group consisting of HG, GR, RG and AR,

(ii) said VL CDR2 has the sequence of SEQ ID NO:11,

(iii) said VL CDR3 has the sequence of SEQ ID NO:12,

(iv) said VH CDR1 has the sequence of SEQ ID NO:13,

(v) said VH CDR2 has the sequence of SEQ ID NO:14, and

(vi) said VH CDR3 has the sequence of SEQ ID NO:16, wherein positions 8-10 of SEQ ID NO:16 have an amino acid sequence selected from the group consisting of THW, YNW, TTW and STY.

18. (Original) An anti-CD22 antibody of claim 17, wherein said VL CDR1 has the sequence of SEQ ID NO:7.

19. (Original) An anti-CD22 antibody of claim 17, wherein said VH CDR3 has the sequence of SEQ ID NO:16.

20. (Original) An anti-CD22 antibody of claim 17, wherein said VL chain has the sequence of SEQ ID NO:20.

21. (Original) An anti-CD22 antibody of claim 17, further wherein said VL CDR1 has the sequence of SEQ ID NO:7 and said VH CDR3 has the sequence of SEQ ID NO:16.

22. (Previously presented) An anti-CD22 antibody of claim 17, wherein said VH chain has the sequence of SEQ ID NO:21.

23. (Previously Presented) An anti-CD22 antibody of claim 17, wherein said VL chain has the sequence of SEQ ID NO:20 and said VH chain has the sequence of SEQ ID NO:21, except that, optionally, said VL chain has a cysteine in place of glycine at position 100 and said VH chain has a cysteine in place of arginine at position 44, as these positions are numbered according to the "Kabat Numbering".

24. (Original) An anti-CD22 antibody of claim 17, wherein said antibody is selected from the group consisting of an scFv, a dsFv, a Fab, or a F(ab')₂.

25. (Previously Presented) A chimeric molecule comprising a therapeutic moiety or detectable label conjugated or fused to an antibody that specifically binds CD22, said anti-CD22 antibody having a variable light (VL) chain comprising three complementarity determining regions (CDRs), and a variable heavy (VH) chain comprising three CDRs, wherein

- (i) said VL chain CDR1 has the sequence of SEQ ID NO:7, wherein positions 4-5 of SEQ ID NO:7 have an amino acid sequence selected from the group consisting of HG, GR, RG and AR,
- (ii) said VL CDR2 has the sequence of SEQ ID NO:11,
- (iii) said VL CDR3 has the sequence of SEQ ID NO:12,
- (iv) said VH CDR1 has the sequence of SEQ ID NO:13,
- (v) said VH CDR2 has the sequence of SEQ ID NO:14, and

(vi) said VH CDR3 has the sequence of SEQ ID NO:16, wherein positions 8-10 of SEQ ID NO:16 have an amino acid sequence selected from the group consisting of THW, YNW, TTW and STY.

26. (Original) A chimeric molecule of claim 25, wherein said VL CDR1 has the sequence of SEQ ID NO:7.

27. (Original) A chimeric molecule of claim 25, wherein said VH CDR3 has the sequence of SEQ ID NO:16.

28. (Original) A chimeric molecule of claim 25, wherein said VL chain has the sequence of SEQ ID NO:20.

29. (Original) A chimeric molecule of claim 25, further wherein said VL CDR1 has the sequence of SEQ ID NO:7 and said VH CDR3 has the sequence of SEQ ID NO:16.

30. (Original) A chimeric molecule of claim 25, wherein said VH chain has the sequence of SEQ ID NO:21.

31. (Previously Presented) A chimeric molecule of claim 25, wherein said VL chain has the sequence of SEQ ID NO:20 and said VH chain has the sequence of SEQ ID NO:21, except that, optionally, said VL chain has a cysteine in place of glycine at position 100 and said VH chain has a cysteine in place of arginine at position 44, as these positions are numbered according to the "Kabat Numbering".

32. (Original) A chimeric molecule of claim 25, wherein said antibody is selected from the group consisting of an scFv, a dsFv, a Fab, or a F(ab')₂.

33. (Original) A chimeric molecule of claim 25, wherein the therapeutic moiety is selected from the group consisting of a cytotoxin, a drug, a radioisotope, or a liposome loaded with a drug or a cytotoxin.

34. (Original) A chimeric molecule of claim 33, wherein the therapeutic moiety is a cytotoxin selected from the group consisting of ricin A, abrin, ribotoxin, ribonuclease, saporin, calicheamycin, a mutated diphtheria toxin, a mutated *Pseudomonas* exotoxin A ("PE"), and botulinum toxins A through F.

35. (Currently Amended) A chimeric molecule of claim 34, wherein said mutated PE is selected from the group consisting of PE35, PE38, PE38KDEL, PE40, PE4E, and PE38QQR, optionally in which said mutated PE has a glycine, alanine, valine, leucine, or isoleucine residue rather than an arginine residue at a position corresponding to position 490 of SEQ ID NO:24 (wild-type PE).

36. (Currently Amended) A chimeric molecule of claim 35, wherein said mutated PE has an alanine residue rather than an arginine residue at a position corresponding to position 490 of SEQ ID NO:24 (wild-type PE).

37. (Previously Presented) A composition comprising (a) a pharmaceutically acceptable carrier and (b) a chimeric molecule comprising an antibody conjugated or fused to a therapeutic moiety or a detectable label, wherein said antibody specifically binds CD22, said anti-CD22 antibody has a variable light (VL) chain comprising three complementarity determining regions (CDRs), and a variable heavy (VH) chain comprising three CDRs, further wherein

(i) said VL chain CDR1 has the sequence of SEQ ID NO:7, wherein positions 4-5 of SEQ ID NO:7 have an amino acid sequence selected from the group consisting of HG, GR, RG and AR,

(ii) said VL CDR2 has the sequence of SEQ ID NO:11,

(iii) said VL CDR3 has the sequence of SEQ ID NO:12,

(iv) said VH CDR1 has the sequence of SEQ ID NO:13,
(v) said VH CDR2 has the sequence of SEQ ID NO:14, and
(vi) said VH CDR3 has the sequence of SEQ ID NO:16, wherein positions 8-10 of SEQ ID NO:16 have an amino acid sequence selected from the group consisting of THW, YNW, TTW and STY.

38. (Original) A composition of claim 37, wherein said VL CDR1 has the sequence of SEQ ID NO:7 and said VH CDR3 has the sequence of SEQ ID NO:16.

39. (Original) A composition of claim 37, wherein the therapeutic moiety is selected from the group consisting of a cytotoxin, a drug, a radioisotope, or a liposome loaded with a drug or a cytotoxin.

40. (Original) A composition of claim 37, wherein the therapeutic moiety is a cytotoxin selected from the group consisting of ricin A, abrin, ribotoxin, ribonuclease, saporin, calicheamycin, diphtheria toxin or a cytotoxic subunit or mutant thereof, a mutated *Pseudomonas* exotoxin A ("PE"), and botulinum toxins A through F.

41. (Currently Amended) A composition of claim 40, wherein said PE is selected from the group consisting of PE35, PE38, PE38KDEL, PE40, PE4E, and PE38QQR, and optionally, said mutated PE has a glycine, alanine, valine, leucine, or isoleucine residue rather than an arginine residue at a position corresponding to position 490 of SEQ ID NO:24 (wild-type PE).

42. (Currently Amended) A composition of claim 41, wherein said arginine residue at a position corresponding to position 490 of SEQ ID NO:24 (wild-type PE) is replaced by alanine.

43-49. (Canceled)

50. (Currently Amended) A method of inhibiting growth of a CD22⁺ cancer cell, wherein said method comprises by contacting said cell with a chimeric molecule comprising

(a) an antibody that binds to CD22, said anti-CD22 antibody has a variable light (VL) chain comprising three complementarity determining regions (CDRs), and a variable heavy (VH) chain comprising three CDRs, further wherein

(i) said VL chain CDR1 has the sequence of SEQ ID NO:7, wherein positions 4-5 of SEQ ID NO:7 have an amino acid sequence selected from the group consisting of HG, GR, RG and AR,

(ii) said VL CDR2 has the sequence of SEQ ID NO:11,

(iii) said VL CDR3 has the sequence of SEQ ID NO:12,

(iv) said VH CDR1 has the sequence of SEQ ID NO:13,

(v) said VH CDR2 has the sequence of SEQ ID NO:14, and

(vi) said VH CDR3 has the sequence of SEQ ID NO:16, wherein positions 8-10 of SEQ ID NO:16 have an amino acid sequence selected from the group consisting of THW, YNW, TTW and STY, and,

(b) a therapeutic moiety,

wherein, following said contacting, said therapeutic moiety inhibits growth of said cell.

51. (Original) A method of claim 50, further wherein said VL CDR1 has the sequence of SEQ ID NO:7 and said VH CDR3 has the sequence of SEQ ID NO:16.

52. (Previously Presented) A method of claim 50, wherein said VL chain has the sequence of SEQ ID NO:20 and said VH chain has the sequence of SEQ ID NO:21, except that, optionally, said VL chain has a cysteine in place of glycine at position 100 and said VH chain has a cysteine in place of arginine at position 44, as these positions are numbered according to the "Kabat Numbering".

53. (Original) A method of claim 50, wherein said antibody is selected from the group consisting of an scFv, a dsFv, a Fab, or a F(ab')₂.

54. (Original) A method of claim 50, wherein said therapeutic moiety is selected from the group consisting of a cytotoxin, a drug, a radioisotope, or a liposome loaded with a drug or a cytotoxin.

55. (Original) A method of claim 54, wherein the therapeutic moiety is a cytotoxin selected from the group consisting of ricin A, abrin, ribotoxin, ribonuclease, saporin, calicheamycin, a mutated diphtheria toxin, a mutated *Pseudomonas* exotoxin A ("PE"), and botulinum toxins A through F.

56. (Currently Amended) A method of claim 55, wherein said PE is selected from the group consisting of PE35, PE38, PE38KDEL, PE40, PE4E, and PE38QQR and, optionally, has a glycine, alanine, valine, leucine, or isoleucine residue in place of an arginine residue at a position corresponding to position 490 of SEQ ID NO:24 (wild-type PE).

57. (Currently Amended) A method of claim 56, wherein said arginine residue at a position corresponding to position 490 of SEQ ID NO:24 (wild-type PE) is replaced by alanine.

58. (Withdrawn) A method for detecting the presence of a CD22+ cancer cell in a biological sample, said method comprising:

(a) contacting cells of said biological sample with an antibody that specifically binds to CD22, said anti-CD22 antibody has a variable light (VL) chain comprising three complementarity determining regions (CDRs), and a variable heavy (VH) chain comprising three CDRs, further wherein

- (i) said VL chain CDR1 has the sequence of SEQ ID NO:7, wherein positions 4-5 of SEQ ID NO:7 have an amino acid sequence selected from the group consisting of HG, GR, RG and AR,
- (ii) said VL CDR2 has the sequence of SEQ ID NO:11,
- (iii) said VL CDR3 has the sequence of SEQ ID NO:12,
- (iv) said VH CDR1 has the sequence of SEQ ID NO:13,

(v) said VH CDR2 has the sequence of SEQ ID NO:14, and
(vi) said VH CDR3 has the sequence of SEQ ID NO:16, wherein positions 8-10 of SEQ ID NO:16 have an amino acid sequence selected from the group consisting of THW, YNW, TTW and STY,
(b) washing said cells to remove unbound antibody, and
(c) detecting the presence or absence of bound antibody,
wherein detecting the presence of said antibody indicates the presence of a CD22+ cancer cell in said sample.

59. (Withdrawn) A method of claim 58, further wherein said VL CDR1 has the sequence of SEQ ID NO:7 and said VH CDR3 has the sequence of SEQ ID NO:16.

60. (Withdrawn) A method of claim 58, further whether said antibody is attached to a detectable label.

61. (Previously Presented) A kit for detecting the presence of a CD22+ cancer cell in a biological sample, said kit comprising:

- (a) a container, and
- (b) an antibody that binds to CD22, said anti-CD22 antibody has a variable light (VL) chain comprising three complementarity determining regions (CDRs), and a variable heavy (VH) chain comprising three CDRs, further wherein
 - (i) said VL chain CDR1 has the sequence of SEQ ID NO:7, wherein positions 4-5 of SEQ ID NO:7 have an amino acid sequence selected from the group consisting of HG, GR, RG and AR,
 - (ii) said VL CDR2 has the sequence of SEQ ID NO:11,
 - (iii) said VL CDR3 has the sequence of SEQ ID NO:12,
 - (iv) said VH CDR1 has the sequence of SEQ ID NO:13,
 - (v) said VH CDR2 has the sequence of SEQ ID NO:14, and

(vi) said VH CDR3 has the sequence of SEQ ID NO:16, wherein positions 8-10 of SEQ ID NO:16 have an amino acid sequence selected from the group consisting of THW, YNW, TTW and STY.

62. (Original) A kit of claim 61, further wherein said VL CDR1 has the sequence of SEQ ID NO:7 and said VH CDR3 has the sequence of SEQ ID NO:16.

63. (Original) A kit of claim 61, further wherein said antibody is fused or conjugated to a detectable label.